Scientists reflect Parkinson’s symptoms in mice – can the following humans be?

Parkinson’s disease is the second most common nervous condition after dementia, where more than 150,000 people live in Australia with this condition.

The research team, led by Professor Kay, has spent more than a decade in studying the biological mechanisms on which the situation is based, with the aim of finding new treatments to slow or stop their progress.

In 2017, the team published a paper in Acta NeuropathologyAnd specifying for the first time the presence of an abnormal form of protein – called sod1 – in the brains of patients who were diagnosed with Parkinson’s disease.

Usually, SOD1 protein provides protective benefits for the brain, but in Parkinson’s patients, it becomes flawed, causing protein clumps and damage to the brain cells.

The latest study conducted by the same team as the University of Sydney, published in Acta Neuropathologica CommunicationsandIt builds on this research. It found that the targeting of the defective SOD1 protein with the treatment of the drug has improved the function of the kinetic in the mice that was raised over symptoms of paralysis.

“All the mice that we treated with them have witnessed a dramatic improvement in their motor skills, a really promising sign that they may be effective in treating people with Parkinson’s disease as well,” said Professor Double.

“We were hoping that by treating this broken protein, we may be able to improve the symptoms that resemble Parkinson’s in the mice that we were treating – but even we are surprised by the success of the intervention.”

methodology

The study included two groups of mice that were born to infection with symptoms similar to Parkinson’s. One group of mice was treated with a private copper supplement for three months, while the other was fake.

During the study, the mice that receive the imaginary medicine saw a decrease in its motor symptoms. However, the mice that receive the private copper supplement did not develop movement problems.

“The results exceeded our expectations and suggested, once additional studies, this treatment approach may slow the development of Parkinson’s disease in humans,” said Professor Dawn.

What is Parkinson’s disease?

Parkinson’s disease is a degenerative nervous disorder where the cells produced dopamine die in the brain, which leads to a group of symptoms including tremors, muscle stiffness, slow movement and a weak balance.

Nowadays, there is no known treatment and limited treatments only, although researchers hope to understand the causes of the disease will improve treatments.

“With our growth of Parkinson’s disease, we find that there are many factors that contribute to their development and progress in humans – and it is possible that the defective forms of SOD1 protein are one of them.

“Just as researchers in HIV found, Parkinson’s disease is a complex condition that probably requires multiple interventions. One treatment may have a small effect when used alone, but when associated with other interventions, it contributes to a great year improvement in health.”

The next step for researchers is to determine the best way to target the defective SOD1 protein in a clinical trial, which can be the beginning of a new treatment to slow the development of Parkinson’s disease.